title: Diagnostic challenges during pretreatment long-term follow-up in a patient with FIP1L1-PDGFRA-positive eosinophilia.
abstract: Obtaining a precise characterization of eosinophilia is crucial, as successful treatment relies on the underlying etiology of the disease. Platelet-derived growth factor receptor alpha-related disorders were first specified in 2008 as a distinct group of clonal eosinophilic disorders with exceptional responsiveness to imatinib. We herein present the case of a man with myeloid neoplasm and eosinophilia in whom a definitive diagnosis could not be adequately made based on histopathological features who was ultimately diagnosed only after extensive molecular analyses and successfully treated with imatinib. In addition, we discuss the diagnostic and therapeutic approaches to treating patients presenting with eosinophilia.
authors: Clinic for Hematology, Clinical Center of Serbia, Serbia.
authors: Danijela
authors: D
authors: Lekovic
authors: Andrija
authors: A
authors: Bogdanovic
authors: Maja
authors: M
authors: Perunicic-Jovanovic
authors: Gradimir
authors: G
authors: Jankovic
authors: Mirjana
authors: M
authors: Gotic
authors: Ivo
authors: I
authors: Elezovic
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D004802:Eosinophilia / Q000188:drug therapy* / Q000378:metabolism; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000187:drug effects / Q000302:isolation & purification* / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000187:drug effects / Q000302:isolation & purification* / Q000378:metabolism; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000187:drug effects / Q000302:isolation & purification* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha